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Abstract
Background:  Solitary fibrous tumors (SFT) represent a rare entity of soft tissue tumors.
Previously considered being of serosal origin and solely limited to the pleural cavity the tumor has
been described in other locations, most particularly the head and neck. Extrathoracic SFT in the
soft tissues of the trunk and the extremities are very rare. Nine cases of this rare tumor entity are
described in the course of this article with respect to clinicopathological data, follow-up and
treatment results.
Methods:  Data were obtained from patients' records, phone calls to the patients' general
practitioners, and clinical follow-up examination, including chest X-ray, abdominal ultrasound, and
MRI or computed tomography.
Results: There were 6 females and 3 males, whose age at time of diagnosis ranged from 32 to 92
years (mean: 62.2 years). The documented tumors' size was 4.5 to 10 cm (mean: 7 cm). All tumors
were located in deep soft tissues, 3 of them epifascial, 2 subfascial, 4 intramuscular. Four tumors
were found at the extremities, one each at the flank, in the neck, at the shoulder, in the gluteal
region, and in the deep groin. Two out of 9 cases were diagnosed as atypical or malignant variant
of ESFT. Complete resection was performed in all cases. Follow-up time ranged from 1 to 71
months. One of the above.mentioned patients with atypical ESFT suffered from local relapse and
metastatic disease; the remaining 8 patients were free of disease.
Conclusion: ESFT usually behave as benign soft tissue tumors, although malignant variants with
more aggressive local behaviour (local relapse) and metastasis may occur. The risk of local
recurrence and metastasis correlates to tumor size and histological status of surgical resection
margins and may reach up to 10% even in so-called "benign" tumors. Tumor specimens should be
evaluated by experienced soft tissue pathologists. The treatment of choice is complete resection
followed by extended follow-up surveillance.
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Background
Solitary fibrous tumors (SFT) – previously known as
benign fibrous mesotheliomas – were considered being of
serosal origin and being exclusively located in the thoracic
cavity as pleural fibrous tumors. More recently, however,
SFT have been reported in many extrapleural locations
such as the head and neck region; in particular, the
meninges, the orbita, the nasal and oral cavity, the salivary
glands, and the visceral organs, the retroperitoneum, and
the pelvic space. Extrapleural solitary fibrous tumors
(ESFT), especially those at the extremities, still represent a
rare entity of soft tissue tumors. In a previous study extra-
pleural solitary fibrous tumors (ESFT) counted for 0.6%
of all soft tissue tumors, sent in for analysis [1]. In fact, by
taking into account the bias caused by the fact that rare
tumor specimens accumulate at specialised institutions,
the general proportion might be much smaller. Usually
the tumor is of benign behaviour (showing no local recur-
rence or metastasis), but malignant variants have also
been described and local recurrence as well as metastasis
may occur depending on the initial tumor size and the
histological status of the surgical resection margins [1-18].
We report 9 cases of ESFT including 4 tumors localized at
the extremities with clinicopathological, immunohisto-
chemical and follow-up data.
Methods
From January 1999 to May 2005, nine patients were diag-
nosed with extrapleural SFT at our institutions. Data were
obtained from patients records and phone calls to the
patients and their general practitioners.
Pathological examination
Preoperative incisional biopsy specimens were obtained
in 4 of 9 cases. The resection specimens were examined
regarding tumor size, exact location, extension to adjacent
soft tissues, and cut surface. A macroscopic photograph of
cut surface was obtained in selected cases.
Histopathological evaluation was performed by experi-
enced soft tissue pathologists.
The criteria for histopathological diagnosis included the
widely accepted characteristic features of SFT (WHO 2003:
patternless growth pattern, composed of round to spin-
dle-shaped fibroblastic cells set in a collagenous matrix,
hemangiopericytoma-like vasculature pattern with often
hyalinized thickened vessel walls and characteristic
immunohistochemical findings). Light microscopical
analysis was based on H&E stained slides. Immunohisto-
chemical analysis included the following antibodies
(table 1): vimentin, CD 34, CD 99, BCL-2, keratin AE1/
AE3, keratin MNF116, EMA, S-100-protein and Ki-67
(antibody MIB-1).
Follow-up data were available for all patients and con-
sisted of clinical examination, chest X-ray, abdominal
ultrasound and computed tomography or MRI of the
tumor site. Follow-up time ranged from 1 to 71 months
(mean: 26.5 months).
Results
The patients included 6 women and 3 men. Their age at
time of diagnosis ranged from 32 to 92 years and averaged
62.2 years. Tumors were painless or became symptomatic
by their mass effect, causing localized pain, or as in one
patient, hypaesthesia. There were no other (especially no
generalized) symptoms. The tumors existed 5 months to
5 years before being diagnosed. All tumors were located in
deep soft tissues, 3 of them epifascial, 2 subfascial, 4 intra-
muscular. Four tumors were located at the extremities
(thigh, fossa poplitea (Fig. 1), 2× lower arm (Fig. 2)) and
one each in the flank, the neck, at the shoulder, in the
deep groin, and in the gluteal region. The diameters of the
tumors ranged from 4.5 to 10 cm (mean: 7 cm). In 7
patients, primary resection could be performed with free
surgical margins; four of them were primarily incisional
biopsied. In one patient, treated externally, the resection
had to be considered a R1-resection due to an intraopera-
tive tumor incision with possible contamination of the
situs. Whether or not this will influence the long term out-
come cannot yet be determined because of a follow-up
time of 1 month. Another patient with unfavourable clin-
ical course (Patient 5) presented at our institution after
pre-treatment at another institution 2 years before consist-
ing of incomplete primary resection and secondary resec-
tion then with free margins, followed by 60 Gy of
radiation. This patient showed extensive local recurrence
and an amputation at upper arm level had to be per-
formed. Five months later, the patient presented again
with two new metastases: one in the right axilla and
another one epifascial at the right subscapular region
which were resected with free surgical margins. At the time
of this study all other patients had no evidence (NED) of
disease. The detailed clinical findings are summarized in
table 2.
Table 1: Antibodies
Antibody Source Dilution Clone
CD 99 DAKO 1:25 12E7
CD 34 Immunotech 1:2000 QBEND10
BCL-2 DAKO 1:6 124
Vimentin DAKO 1:8000 V9
EMA DAKO 1:50 E29
Keratin MNF 116 DAKO 1:1600 MNF 116
Keratin AE1/AE3 DAKO 1:800 AE1/AE3
Ki67 DAKO 1:800 MiB1
S100 DCS 1:200 15E2E2
Detailed data about the antibodies usedBMC Surgery 2006, 6:10 http://www.biomedcentral.com/1471-2482/6/10
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Pathological findings
The tumors appeared as solid, mostly well-circumscribed
and smooth to firm soft tissue masses. The cut surface
appeared white to brown-yellow. Considerable tumor
necrosis was evident in case 5 and 8 (Fig. 3).
The tumors were composed of fibroblastic appearing cells,
usually showing a characteristic "patternless" growth pat-
tern with small fascicular areas (Fig. 4). The vessels
adopted a hemangiopericytoma-like growth pattern con-
sisting of elongated and dilated vessels with thickened,
often hyalinized walls (Fig. 5). The tumor matrix included
variable amounts of partly hyalinzed collagen bundles.
Truly infiltrative growth patterns could not be detected,
although vascular infiltration was evident in one case
(Patient 5). The tumor cells were characterized by "ovally"
to spindle-shaped nuclei, sometimes resembling neural
cytologic features (i.e., wavy nuclei). The mitotic rate in
morphologically benign SFTs was less than 4/10 HPF
(high power field: objective × 40). Two lesions were diag-
nosed as atypical variant of ESFT due to a markedly
increased cellularity, cellular atypia (nuclear pleomor-
phism, nuclear hyperchromasia), increased mitotic index
and tumor necrosis (Patient 5+8).
All neoplasms stained variably positive for CD 34, CD 99,
BCL-2 and vimentin. An additional expression of smooth
muscle actin was seen in 3 of 5, muscle specific actin in 1
of 3 and expression of desmin could be detected in 2 of 4
examined cases. No positive keratin and S100 immunore-
action was noted, whereas EMA could be detected focally
in 2 cases. The proliferation rate ranged from 1 to 10%. A
detailed summary of the histopathological findings is
given in table 3.
MRI of SFT Figure 2
MRI of SFT. MRI of a solitary fibrous tumor depicting a rel-
atively well circumscribed soft tissue tumor in the forearm.
clinical aspect of SFT Figure 1
clinical aspect of SFT. Clinical aspect of a solitary fibrous 
tumor of the lower left leg: swelling with soft tissue mass 
(same patient as in fig. 3).B
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Table 2: Clinical findings
patient gender age at time 
of diagnosis 
(years)
localisation/
depth of 
tumor
size of primary 
tumor (cm)
presentatio
n status of 
tumor
symptoms on first 
presentation
pre-operative 
incisional 
biopsy
surgical margins 
in final 
procedure
local 
recurrenc
e
metastasis secondary procedures status at last 
follow-up 
(months)
1 male 40 neck/
epifascial
10 × 8 × 10 primary neck pain no negative no no none alive, NED, 21
2 male 56 shoulder/
epifascial
4.5 × 4 × 2.5 primary painless mass no negative no no none alive, NED, 56
3 female 85 m. vastus 
lateralis
4.8 × 3 × 2 primary painless mass yes negative no no none alive, NED, 71
4 female 32 m. iliopsoas 4.5 × 3.3 × 2.1 primary groin pain no negative no no none alive, NED, 38
5 male 57 lower arm/
flexor 
muscles
no data local 
recurrence
painless mass no negative yes, after 
2 years
yes, after 
3 years
axillary dissection, amputation 
at upper arm level resection 
of two metastases
alive, NED, 6
6 female 59 lower arm/
flexor 
muscles
6.2 × 3.5 × 4.2 primary painless mass yes negative no no none alive, NED 12
7 female 92 flank/
epifascial
10 × 10 × 9 primary painless mass yes negative no no none alive, NED 28
8 female 52 fossa 
poplitea/
subfascial
9.5 × 5.4 × 6.5 primary pain in fossa 
poplitea, 
paraesthesia 
lateral lower leg
yes negative no no none alive, NED 6
9 female 87 gluteal/
subfascial
6.6 × 5.6 × 3.7 primary Painless swelling no R1 no no none Alive, NED 1
Summary of the patients' data (no evidence of disease: NED)BMC Surgery 2006, 6:10 http://www.biomedcentral.com/1471-2482/6/10
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Discussion
SFT represents a distinct entity within the wide range of
soft tissue tumors. Its cellular origin is believed to be
fibroblastic in type. Most cases of formerly diagnosed
"hemangiopericytomas" seemingly share essential fea-
tures with SFT and may indeed represent true SFT. Accord-
ing to overlapping histological criteria between SFT and
hemangiopericytoma, SFT represents a wider range of
neoplasias (probably in fact including the former "favour-
ite" diagnosis of hemangiopericytoma) which should best
be regarded as a "waste basket" and be considered a mere
diagnosis of exclusion. The lipomatous variant of SFT
("lipomatous hemangiopericytoma") includes a mature
fat component intermingling with typical areas of SFT.
Rare myxoid SFT may cause considerable problems in dif-
ferential diagnosis to more aggressive soft tissue neo-
plasms or soft tissue tumors of another differentiation.
Branching and ectatic blood vessels typical for SFT known
as hemangiopericytoma-like vessels may be a feature of
several other predominantly malignant soft tissue tumors
(e.g. synovial sarcomas or malignant peripheral nerve
sheath tumors), implicating that a wider range of other
soft tissue neoplasias has to be considered in the his-
topathological differential diagnosis of SFT. The so-called
"patternless pattern" or the combination of different his-
tological patterns such as storiform, fascicular, neuraltype,
diffuse sclerosing, and heringbone growth pattern may
lead to a wrong diagnosis [19]. Therefore, it is evident that
an experienced soft tissue pathologist should evaluate the
specimens. For differential diagnosis, so-called hemangi-
opericytoma, synovial sarcoma, dermatofibrosarcoma
protuberans, leiomyosarcoma, malignant peripheral
nerve sheath tumor, and liposarcoma, should be taken
into consideration. Positron emission tomography (PET)
may be helpful to distinguish between a malignant and a
benign variant of the tumor [20-22], but the gold standard
for diagnosis remains incisional biopsy.
Extrathoracic solitary fibrous tumors (ESFT) by now have
been reported at almost every anatomic location, but
reports of tumors at the extremities or intramuscular
Microscopic aspect of SFT (b) Figure 5
Microscopic aspect of SFT (b). Microscopic aspect of a 
solitary fibrous tumor, higher magnification: fibroblastic, 
partly "neural-like" tumor cells lying in a fibrous, partly hyali-
nized matrix, hemangiopericytoma-like blood vessels.
Macroscopic aspect of SFT Figure 3
Macroscopic aspect of SFT. Macroscopic aspect of a soli-
tary fibrous tumor: cut surface of a well circumscribed 
tumor; white to tan coloured cut surface with some deeply 
yellow necrotic areas (atypical/malignant solitary fibrous 
tumor, case 8).
Microscopic aspect of SFT (a) Figure 4
Microscopic aspect of SFT (a). Microscopic aspect of a 
solitary fibrous tumor: "Patternless" growth pattern with cel-
lular (right half) and some myxoid (left half) areas, hemangi-
opericytoma-like wide blood vessels.B
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Table 3: Histological results
patient CD34 
reactivity
CD99 
reactivity
BCL2 
reactivity
Vimentin 
(V9) 
reactivity
actin 
HHF35
smooth 
muscle 
actin
desmin S100 keratin MNF116 EMA MiB1 necrosis average 
mitoses/
10 HPF
malignant 
component
additional 
tests
1 focal 
positive
focal 
positive
p o s i t i v e p o s i t i v e --------a b s e n t < 4 a b s e n t
2 focal 
positive
- - positive - focal 
positive
- negative negative - - 1% absent <4 absent
3 positive positive - positive focal 
positive
focal 
positive
focal 
positive
negative negative - - 5% absent <4 loss on 
chromoso
me 13q
4 focal 
positive
focal 
positive
focal 
positive
focal 
positive
-f o c a l  
positive
focal 
positive
- negative negative - 1–2% absent <1 absent
5 positive positive - positive - - - negative negative - negative 5–10% present 10 present HMB 45 
negative
6 focal 
positive
positive positive positive negative negative negative negative negative negative focal 
positive
<5% absent <4 absent Keratin 
AE1/AE3 
negative
7 positive positive positive positive - - - - - - focal 
positive
<1% absent <4 absent
8 positive positive positive positive - - negative negative negative negative negative 5% present 3 present HMB 45 
negative 
Keratin 
AE1/AE3 
focal
9 positive positive positive focal 
positive
negative negative - - - - - 5–10% absent <4 absent
Summary of the histological results (-: not tested)BMC Surgery 2006, 6:10 http://www.biomedcentral.com/1471-2482/6/10
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tumors as well as tumors with malignant clinical behav-
iour or atypical histologic features are rare [1-18].
Other series of ESFT's showed almost equal distribution of
the incidence for male and female, with patients' ages
ranging from the third to the eighth or ninth decade with
a maximum in the sixth decade concurring with our data
[3,7,8].
Some studies suggested a very low rate of recurrence and
metastasis [8,11,23], whereas other authors indicated a
possibly increased relapse rate with extended follow-up
periods. In their studies Vallat-Decouveleare et al. and
Gold et al. [3] in their studies found local recurrence in
4.3% and 6.7% and metastasis in 5.4% and 5.3%, respec-
tively. Tumor relapse occurred after up to 168 months, but
most of the metastasis or local recurrences were diagnosed
within the first two years after initial treatment. Sites of
distant metastasis were lung, liver, bones, mesentery,
omentum, mediastinum and retroperitoneum with pref-
erence for lung and liver [1,3].
Vallat-Decouveleare suggested atypical histologic features,
such as nuclear atypia, areas of increased cellularity,
necrosis and 4 or more mitoses per 10 HPF as being pre-
dictive for clinical malignant behaviour of the tumor and
found local or distant relapse in those cases in 80%, but
also reported a case of clinically malignant behaviour of a
histological benign appearing case. Recurrent tumor spec-
imens showed a higher grade of atypia than the primary
tumor but usually retained their immunohistochemical
profile. Gold's data proposed to add the size of the pri-
mary tumor as well as the resection status to the predictive
factors of clinical behaviour. Positive surgical resection
margins and primary tumor sizes of more than 10 cm
were positively correlated with unfavourable clinical out-
come.
In our series, the only patient with recurrent disease and
metastasis was primarily resected incompletely, underlin-
ing this suggestion. In the recurrent tumor specimen
increased atypia was seen, but if this atypia had already
been present in the primary tumor and therefore could be
considered as of predictive value cannot be determined.
The recurrence occurred 2 years and the metastasis 2 ½
years after primary resection and following radiation.
Detailed histopathological information about the pri-
mary tumor could not be obtained.
Complete surgical resection is commonly accepted as
treatment of choice for ESFT. Due to improved techniques
in reconstructive surgery, even large lesions can usually be
completely resected, preserving the limbs. Amputations
should be limited to extended or recurrent tumors. Befit-
ting the rareness of this entity reports of radiation therapy
and chemotherapy of ESFT are anecdotal and so far, no
significant benefit of adjuvant treatment has been
reported. In some cases, especially malignant variants or
incomplete resections with no further surgical option, it
may although be used [1,3]. This concurs with the find-
ings for intrathoracic SFT [24,25].
According to the late recurrence or metastasis, long fol-
low-up periods (at least 15 years) should be maintained
with closer follow-up during the first two years. In coop-
erative patients a life long follow-up may be recom-
mended. Follow-up should include clinical examination
as well as abdominal ultrasound and chest x-ray.
Conclusion
Soft Tissue sarcoma specimens should be evaluated by
experienced soft tissue pathologists for correct diagnosis
of SFT and detection of atypia. SFT with atypical histologic
features, such as nuclear atypia, areas of increased cellular-
ity, necrosis and 4 or more mitoses per 10 HPF, tumor
sizes of more than 10 cm and incomplete resection are
positively correlated with local recurrence and metastatic
disease. Therefore complete resection at an early stage
should be the main purpose of surgical treatment. Follow-
up should be maintained for 10 years.
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